Users consuming data from enterprise resources use Cognos as their main reporting tool for operational data. These videos are designed as both training tools, report training, and reference guides for individuals in the reporting environment. The videos listed below are based on user roles and licensing.
This video demonstrates how to revert to an older version of a Cognos report. MotioCI relieves you from needing to save multiple versions. Cognos users can now revert back to a previous version.
This video demonstrates how to restore a deleted Cognos report or folder. Cognos users can now recover deleted reports and folders.
Demonstration on creating a Cognos schedule, including creating a report view and setting prompt selections.
Completion of COG 101 is required. Cognos Analytics Authoring offers report authoring capabilities including advanced formatting and filtering, prompt generation, and paging controls. This tool allows for a robust experience in data handling and report construction.
Videos (to be watched sequentially - total run time is under 2 hours)
Cognos is a web-based suite of tools from IBM that offers a full range of business intelligence (BI) capabilities including reports, analysis, dashboards, scorecards, mobile BI and more. Cognos is Purdue’s primary Business Intelligence(BI) tool and is used to access many of the university’s BI environments including those to access student-related data.
Cognos is the system Purdue uses for official reporting on Purdue student data. If you’d like to learn about how to request Cognos access, please visit the Business Intelligence Competency Center Website.
The following Cognos system reports (login required) are recommended by Accounting Services for Research and Sponsored Programs (ASRSP) for administrators to use when monitoring their unit's sponsored projects.
This report displays balances for active projects including totals for direct and indirect expenditures as well as encumbrances by department and/or principal investigator
It can run for negative balances only to monitor deficit spending
Drill through available by project to the GM045 - Sponsored Project Budget Statement
Displays direct and indirect expenditure totals by project against the total budget amount along with project demographic data
Dollars are broken out and shown by Current Accounting Period, Fiscal Year to Date, and Inception to Date
Our annual list of 10 Breakthrough Technologies highlights the technological advances that we think will have the biggest impact on the world in the years to come.
The 35 Innovators Under 35 is our yearly opportunity to take a look at not just where technology is now, but where it’s going and who’s taking it there.
What is AI? It’s the quest to build machines that can reason, learn, and act intelligently, and it has barely begun. We cover the latest advances in machine learning, neural networks, and robots.
Face recognition | Machine learning | Robots | Voice assistants
The Big Story is a home for MIT Technology Review’s most important, ambitious reporting—stories that take a deep look at the technologies that are coming next and what they will mean for us and the world we live in.
Biotechnology is the industry that uses the molecules of life (DNA, RNA, and proteins mostly) to treat and diagnose disease. We report on the latest biomedical science and technological research.
CRISPR | DNA testing | Genetic engineering | Genomic medicine
What is a blockchain? Distributed ledger technology underlies cryptocurrencies like bitcoin and could be the future of money, security, and online privacy. But there’s also a ton of hype.
Bitcoin | Cryptocurrency | Ethereum | ICOs | Smart contracts
Climate change is making the Earth a warmer and weirder place, forcing researchers, companies and governments to understand, confront and adapt to rising dangers.
Battery technology | Carbon sequestration | Clean energy | Electric cars | Geoengineering
Computer technology news and in-depth analysis of computer tech, looking at the latest advances in computing being driven by innovations in everything from microchips to quantum computing.Cloud computing
Cybersecurity | Edge computing | Microchips | Quantum computing | Supercomputing
You can read our most essential coverage of the coronavirus/COVID-19 outbreak for free, and also sign up for our coronavirus newsletter. But please consider subscribing to support our nonprofit journalism.
A look at how technologies from AR/VR, brain-computer interfaces, and chip implants to health trackers, biometrics and social media are changing the most basic aspects of human life—work, friendship, love, aging, sickness, parenting, learning, and building community.
AR | Biohacking | Brain-computer interface | VR
Covid-19 has altered our lives in countless ways. We’re tracking technology that’s responding to the pandemic, with support from The Rockefeller Foundation.
Google, Facebook, Apple, Amazon, and other Silicon Valley Big Tech companies are built on innovation. But how are these corporate behemoths dealing with the ramifications of their power?
Amazon | Apple | Facebook | Google |
Governments around the world are trying to Improve urban life by adopting digital technologies and creating Smart Cities filled with sensors. Who are these projects benefiting and how smart are they?
5G | IoT | Self-driving cars
Humanity is pushing further outside of our atmosphere. We take a look at the space tech coming out of places like NASA, SpaceX, and Blue Origin that is powering the space exploration of tomorrow.
Astronomy | NASA news | Space exploration | SpaceX news | The Moon
Who’s responsible when technology causes harm? We look at how the world is dealing with problems like fake news and misinformation, AI bias, Big Tech’s power, genetic discrimination, privacy intrusions, mass surveillance, and more.
AI Ethics | Kids and tech | Privacy | Tech and health
In today’s world of “business professional” and “business casual” attire, it can be tricky to know the appropriate way to dress for an interview, for work at a conservative company such as a financial institution, or for a place where things are a little more laid back. What makes it even trickier is that what is considered “business professional” at one company, such as non-profit or a software organization, might be considered “business casual” at an accounting firm.
So what is a person to do?!
Regardless of business professional or business casual, women should always avoid showing cleavage and mid-drifts, as well as avoid clothing that is too tight or too short. Both men and women should always choose clothing that covers tattoos, and jewelry should be kept to a minimum (no earrings on men!).
A place to explore new creative opportunities and advance your skills, the School of Continuing and Professional Studies offers a taste of the Pratt experience in an approachable and flexible format. From workshops to semester-long courses, in person or virtually, you’ll learn from leading Pratt faculty, create connections across disciplines, and earn digital credentials for select programs—all fueled by the latest technology and studio environments.
Chemical professionals should seek to advance chemical science while striving for the highest standards of scientific integrity. This includes sharing ideas and information, keeping accurate and complete records, and giving due credit to the contributions of others. Undisclosed conflicts of interest and scientific misconduct, including fabrication, falsification, and plagiarism, are incompatible with this code.
Chemical professionals should be aware of laws and regulations related to the professional conduct of science to ensure that their profession is practiced safely and appropriately.
Chemical professionals should be actively concerned with the health and safety of co‐workers, consumers, and the community. Professionals have a responsibility to serve the public interest and to further advance scientific knowledge. This includes ensuring that public comments are made with care and accuracy to avoid unsubstantiated, exaggerated, or premature statements.
Chemical professionals should treat others with respect and will not engage in discrimination, harassment, bullying, dishonesty, fraud, misrepresentation, coercive manipulation, censorship, or other misconduct. Such actions apply to all professional, research, and learning environments, regardless of whether or not the action alters the content, veracity, or meaning of research findings, and regardless of whether or not the action affects the planning, conduct, reporting, or application of science.
Chemical professionals should take responsibility to act or intercede where possible to prevent misconduct. This includes reporting suspected research misconduct, as well as any discrimination, harassment, bullying, dishonesty, fraud, misrepresentation, coercive manipulation, or censorship.
Chemical professionals should be mindful of Implicit Bias and Unconscious Bias and strive to avoid all bias based on race, gender, age, religion, ethnicity, nationality, sexual orientation, gender expression, gender identity, presence of disabilities, educational background, or other personal attributes.
Chemical professionals should strive to do their work in ways that are safe and sustainable for the environment. This includes continuing to work to develop sustainable products and processes that protect the health, safety, and prosperity of future generations.
Chemical professionals should serve clients faithfully and incorruptibly, respect confidentiality, advise honestly, and charge fairly. Additionally, they should promote and protect the legitimate interests of their employers, comply with safety policies and procedures, fulfill obligations, and safeguard proprietary and confidential business information.
Chemical professionals should strive for continual professional growth both personally and more broadly in the tutelage of others as a trust conferred by society. Professionals have a responsibility to understand limitations of their knowledge, remain current with developments in their field, learn with and encourage others.
For more information about the Department of Career and Professional Advancement, please see our Contacts List.
Topic selection is the process for deciding which courses NICE will produce technology appraisal guidance on. NICE aims to consider all new significant drugs and indications. Health technologies referred to the NICE technology appraisals programme include:
The subject selection process has been designed to support the technology appraisal process so that courses chosen will add value and support healthcare professionals and others to provide care of the best possible quality, which offers the best value for money.
NICE manages this process on behalf of the Department of Health and Social Care. NICE can only begin to appraise a technology when it has been formally referred by the Secretary of State for Health and Social Care.
The aims of the subject selection process are to:
Most courses are identified by the National Institute for Health Research Innovation Observatory at the University of Newcastle. This centre notifies NICE about key, new and emerging healthcare technologies that might be suitable for NICE technology appraisal. It aims to notify NICE of new drugs in development 20 months before marketing authorisation and new indications 15 months before marketing authorisation. These time frames are required by NICE to enable guidance to be published as close as possible to product launch.
Suggestions for technology appraisal guidance on a new medicinal product (that has not yet received a marketing authorisation) should be made by the relevant company through UKPharmaScan. Healthcare professionals, researchers and patients can also suggest potential technologies for NICE to appraise by contacting the National Institute for Health Research Innovation Observatory.
Topic selection decisions are based on the consideration of each potential subject against elimination and prioritisation criteria. The elimination criteria filter out courses unsuitable for guidance development through the technology appraisal programme. A subject will not be considered if the technology has not been granted a marketing authorisation (or equivalent) or if there are no plans for it to receive a marketing authorisation (or equivalent) or if it is identical to:
The following subject areas are also outside the remit of technology appraisal guidance development at NICE:
Topics are not considered unless:
Elimination and filtering is done by the Consultant Clinical Adviser in the subject selection team and includes seeking expert opinion and engaging with the relevant National Clinical Directors. The filtering recommendations are considered by an internal group at NICE, and shared with the Department of Health and Social Care and NHS England.
The importance of each subject is considered against prioritisation criteria prioritisation criteria (PDF) that help the Secretary of State for Health and Social Care decide which courses should be referred to NICE for guidance development through the technology appraisal programme. This includes consideration of the population size, disease severity, resource impact and the value that NICE could add in carrying out a technology appraisal. The prioritisation criteria are:
Prioritisation is also done by the Consultant Clinical Adviser in the subject selection team and is informed by the external expert opinion already sought during filtering. The National Institute for Health Research Innovation Observatory at the University of Newcastle develops technology briefings for potential appraisal topics.
Relevant companies have the opportunity to comment on these technology briefings before the prioritisation recommendations are considered by an internal group at NICE, and shared with the Department of Health and NHS England. The group at NICE meets to decide the next steps for each subject being considered, to ensure the timely production of guidance. The group considers each subject and decides whether it is potentially suitable for NICE appraisal and as a result, whether the scope should be sent out for consultation.
Summary information on subject progress is published on the NICE website. The list of potential courses is handed over to the technology appraisal scoping team to develop the draft scopes for consultation.
Medicinal products marketed in England that do not meet the criteria for referral into the technology appraisal programme can be considered for the highly specialised technologies programme or for a new medicines evidence summary to help inform local decision-making.
NICE’s approach on biosimilars is:
a. NICE will consider similar biological medicinal products notified to it by the National Institute for Health Research Innovation Observatory for referral to the Technology Appraisal subject selection process.
b. These products will usually be considered in the context of a Multiple Technology Appraisal in parallel with their reference products in the indication under consideration.
c. In other circumstances, where it is considered a review of the evidence for similar biological medicinal product is necessary, NICE will consider producing an ‘Evidence summary new medicine’.
d. NICE technology appraisals will use the name of the active drug substance, including reference products and brand named similar biological medicinal products in its documentation where appropriate to inform clinical decision making and to reflect the remit received from Ministers.
e. The Department of Health in England has confirmed that a technology appraisal remit referred to NICE enables NICE to decide to apply the same remit, and the resulting guidance, to relevant licensed biosimilar products which subsequently appear on the market.
f. Evidence summaries will use the brand names of the medicines because substitutability and interchangeability cannot be assumed. Evidence summaries do not make recommendations hence the decision regarding the choice of biosimilar or originator biologic for an individual patient rests with the responsible clinician in consultation with the patient.
Companies that want to suggest that NICE develops guidance on a new pharmaceutical product (one that is not yet licensed or used within the NHS) should notify UK PharmaScan. More information is on the Pharmascan website. Alternatively, please contact the National Institute for Health Research Innovation Observatory.